ArticleBreast cancer research : BCR2013
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.
Article in Breast cancer research : BCR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 98 citations in OpenAlex.
- Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Trial
- Chemotherapy is associated with differential survival outcomes in apocrine carcinoma: A nationwide cohort study from the Japanese National Clinical Database-Breast Cancer Registry.Breast (Edinburgh, Scotland) · 2026Observational
- Invasive Apocrine Carcinoma in a Young Female With Triple Hormone Receptor Positivity: A Case Report.Cureus · 2026Article
- Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors.Breast cancer research : BCR · 2025Article
- Classification of Breast Cancer Through the Perspective of Cell Identity Models.Advances in experimental medicine and biology · 2025Review
- Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC).Indian journal of surgical oncology · 2024Article
- Apocrine Breast Cancer: A Case Report.Cureus · 2024Article
- Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies.Cancers · 2023Review
- Review
- ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!Biomedicines · 2023Review
- Clinicopathological characteristics of HER2-low breast cancer: a retrospective study.Scientific reports · 2023Article
- Article
- Article
- Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers.NPJ breast cancer · 2022Article
- Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy.Journal of personalized medicine · 2022Article
- Apocrine lesions of the breast.Virchows Archiv : an international journal of pathology · 2022Review
- Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers.Cancers · 2021Article
- Obesity and Androgen Receptor Signaling: Associations and Potential Crosstalk in Breast Cancer Cells.Cancers · 2021Review
- Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer.Cancers · 2021Article
- Triple negative breast cancer: special histological types and emerging therapeutic methods.Cancer biology & medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMolecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 transcriptionally defined MA tumors and proposed a new tool to identify these tumors.
methodsWe performed quantitative reverse transcription PCR (qRT-PCR) for ESR1, AR, FOXA1 and AR-related genes, and immunohistochemistry (IHC) for ER, PR, Human Epidermal Growth Factor Receptor 2 (HER2), CK5/6, CK17, EGFR, Ki67, AR, FOXA1 and GCDFP15 and we analyzed clinical features.
resultsMA tumors were all characterized by ESR1(-) AR(+) FOXA1(+) and AR-related genes positive mRNA profile. IHC staining on these tumors showed 93% ER(-), only 58% AR(+) and 90% FOXA1(+). 67% and 57% MA tumors were HER2(3+) and GCDFP15(+), respectively. Almost all MA tumors (94%) had the IHC signature HER2(3+) or GCDFP15(+) but none of the 13 control basal-like (BL) tumors did. Clinically, MA tumors were rather aggressive, with poor prognostic factors.
conclusionMA tumors could be better defined by their qRT-PCR-AR profile than by AR IHC. In addition, we found that HER2 or GCDFP15 protein overexpression is a sensitive and specific tool to differentiate MA from BL in the context of ER negative tumors. A composite molecular and IHC signature could, therefore, help to identify MA tumors in daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.